

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drug types best describes the mechanism of action of the novel agent iberdomide?
 - a. Anti-CD38 antibody
 - b. Bcl-2 inhibitor
 - c. BCMA-targeted agent
 - d. Cereblon E3 ligase modulator (CELMoD)

2. Results of the Phase II KarMMa trial evaluating the investigational BCMA-directed CAR (chimeric antigen receptor) T-cell construct idecabtagene vicleuceel for relapsed/refractory multiple myeloma (MM) included which of the following progression-free survival (PFS) outcomes?
 - a. A durable benefit in a patient population with heavily pretreated disease
 - b. A short-lived benefit in a patient population with heavily pretreated disease

3. The Phase III MAIA trial comparing daratumumab, lenalidomide and dexamethasone (D-Rd) to Rd (lenalidomide and dexamethasone) for patients with newly diagnosed MM ineligible for high-dose chemotherapy and transplant reported which of the following PFS outcomes?
 - a. Improvement on the D-Rd study arm
 - b. Similar PFS on both arms

4. The BELLINI trial investigating the addition of venetoclax to bortezomib and dexamethasone for patients with relapsed/refractory MM reported an improvement in outcomes in which of the following groups of patients?
 - a. Patients with 4;14 translocation
 - b. Patients with 11;14 translocation
 - c. Patients with 17p deletion